In This Section

BiomarkerLIVE Overview

The role of biomarkers and molecular profiling in cancer diagnosis and treatment continues to expand. In oncology, a biomarker can indicate cancer type, how a cancer will progress if left untreated, what specific treatment may be most effective for a given cancer, and how well treatment is working over time. For five of the most common types of cancer (lung, prostate, colorectal, breast, and skin), there are more than 75 biomarkers used in clinical practice. The sheer number of treatment options across tumor types and the complexity of delivering care makes it difficult for cancer care providers to integrate new therapeutics, like biomarker testing, into their practices.

Barriers to using biomarker testing are common. Respondents to ACCC’s 2018 Trending Now in Cancer Care Survey indicate that insurance coverage, reimbursement, and insufficient protocols are among the issues working against the widespread implementation of biomarker testing in oncology practices.

To help cancer care providers surmount these and other barriers and enhance their knowledge of this rapidly evolving treatment area, ACCC launched the first phase of BiomarkerLIVE in April 2019. Since then, ACCC has worked with clinical experts and industry leaders to develop a common lexicon of biomarker terminology to promote better communication among cancer care teams; establish a resource library of materials relevant to cancer biomarkers and biomarker testing; and host a how-to webinar that explores how cancer programs can use these tools to implement effective biomarker testing protocols for their patients.

Building on the success of BiomarkerLIVE’s launch, Phase 2 will help cancer providers better understand what is needed to facilitate the integration of precision medicine into everyday practice. The objective of this phase is twofold:

  • Support the multidisciplinary cancer care team with the development of the infrastructure and expertise necessary to facilitate the integration of precision medicine into everyday practice.
  • Develop new tools and platforms to disseminate relevant educational resources to the multidisciplinary cancer care team.
For more information on this project, please contact the ACCC Provider Education department.

On-Demand Webinars

  • This webinar will review how the steps in the life cycle of a patient specimen can affect its molecular integrity and molecular analysis results. Our expert speaker will define the roles of stewardship across the specimen chain of custody, discuss common factors that compromise specimen fitness for molecular testing, and describe solutions to improve preanalytics and tissue stewardship.

  • Two thought leaders who have deep knowledge of—and experience in—biomarker testing in patients with hematologic malignancies will discuss best practices for biomarker testing in chronic lymphocytic leukemia (CLL) and multiple myeloma based on patient case discussions and the latest guidelines.

  • Take a deeper dive into the differences between germline and somatic mutations and what this means for patients with cancer and their families. Considerations for tumor types where somatic and germline testing comes into play for colorectal, ovarian, pancreatic, and prostate cancers will be discussed.

  • This webinar will help participants better understand the role of laboratory medicine professionals and pathologists in biomarker testing and incorporate a review of testing techniques and applications, lab-specific regulations, and the impact of those regulations on biomarker testing.

  • This on-demand panel discussion provides a review pf the current policies and regulations that drive costs related to biomarker testing.

  • This on-demand webinar will explore the differences between germline and somatic mutations (with case examples), review AMP/ASCO/CAP guidelines, give somatic testing examples, and share findings from a LUNGevity/FORCE patient survey.

  • Gain an introduction to cancer biomarkers and its relevant terminology, review different types of biomarkers, discuss the current landscape of biomarker-driven therapies by tumor type, and implications for cancer care delivery.

Presentations & Abstracts


accc-biomarker-provider-guide-77x100Talking with Your Patients About Biomarker Testing in Cancer Care - Provider Tips
This fact sheet supplies information to assist providers in talking with patients about biomarker testing and its role in their care.

accc-biomarker-patient-guide-77x100Conversation Guide: Biomarker Testing and its Role in Your Cancer Journey
A set of questions to guide patient-provider conversations related to biomarker testing. Type answers in this fillable PDF, or print blank copies for patients to write their own notes.

Biomarker Testing in Practice: Process Improvement Toolkit
Review the four key elements needed when developing a precision medicine program that successfully incorporates biomarker testing.

Application of Biomarkers in Clinical Trials
This white paper details considerations when determining to conduct biomarker testing on a patient, and the role the test results may play in potentially making that patient eligible for future clinical trials.

Cancer Buzz Podcasts

From the ACCCBuzz Blog

  • ACCC Commemorates World Lung Cancer Day—10 Years Strong
    August 01, 2022
    Communities around the globe recognize August 1 as World Lung Cancer Day—a day to commemorate, educate, and support individuals and families impacted by lung cancer. Read highlights on a few ACCC initiatives that are helping cancer care teams better support their patients with this disease.
  • barriers-to-liquid-biopsy-240x160
    Barriers to Liquid Biopsy
    October 14, 2021
    Liquid biopsy, a genetic test that can eliminate some of the most serious potential drawbacks of traditional tissue biopsy, is gaining more traction in cancer care. But there remain significant barriers to its widespread use.
  • Cancer Cell and DNA Strand-cropped
    MMR/MSI Testing Guidelines Proposed—Comments Due March 13
    March 03, 2020

News & Media


Our Partners



Our Supporters

logo-abbvie-200x80 AstraZeneca_200x80 This project is supported by AbbVie, AstraZeneca, Lilly Oncology, and Merck & Co., Inc. BMS-330x80 Phase one of this project was supported by Bristol Myers Squibb.